CEO Summary: Pre-authorization of expensive genetic and molecular tests is fast-becoming a priority for most of the nation’s health insurers. For clinical labs and pathology groups that don’t respond, this trend is a threat. On the other hand, because payers need all the skills and knowledge that labs possess to intelligently manage utilization of molecular […]
Payers Move to Pre-Authorize Expensive Genetic Tests
Opportunity for labs to be paid on value and not as a commodity!
- By Robert Michel
- > From the Volume XVII No. 13 - September 13, 2010 Issue
- Tags: aco, cap, Capitation, care contracts, clinical lab, clinical laboratories, Clinical Laboratory, clinical labs, Clinical pathology, clinical pathology lab, cpt, cpt coding, dark report, diagnostic testing, Diagnostic tests, Fee-for-service, genetic test, genetic testing, genetic tests, genomic testing, impac, informatics, integrated informatics, lab administrator, lab industry, lab test, lab tests, laboratories, laboratory administrator, laboratory organization, laboratory service, laboratory services, laboratory test, managed care, managed care contract, managed care contracts, molecular assay, molecular assays, molecular diagnostic, molecular testing, molecular tests, pathologists, Pathology group, pathology groups, pathology lab, pathology lab test, pathology lab tests, pathology practice, the dark report, the laboratory, utilization management, Value-based reimbursement
